Kenji Yokota - Concepedia

Author

Kenji Yokota

Nagoya Institute of Technology ORCID

Also Known As

K Yokota, K. YOKOTA, K. Yokota, Kenji YOKOTA, Kenji Yokota, Yu Matsui

156

Publications

5.6K

Citations

H-Index

Concepts

All Affiliations

Nagoya Institute of Technology Nagoya University Nagoya University Hospital Niigata Cancer Center Hospital Kumamoto University

About

Kenji Yokota is an author at Nagoya Institute of Technology specializing in engineering, polymer science, and polymer chemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Engineering	16	28	792
2	Medicine	12	13	941
3	Natural Sciences	5	5	137
4	Health Sciences	1	1	20
5	Applied Physics	1	1	21

Kenji Yokota

Publications

5.2K

Citations

H-Index

Page 1

	Year	Citations
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma Jeffrey S. Weber, Mario Mandalà, Michele Del Vecchio, New England Journal of Medicine	2017	2.1K
Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan Shigeaki Suzuki, Nobuhisa Ishikawa, Fumie Konoeda, Neurology	2017	380
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial Alexander Eggermont, Christian U. Blank, Mario Mandalà, The Lancet Oncology Surgical OncologyMedicineMelanomaImmunologyImmune Checkpoint Inhibitor	2021	364
Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study Tomoko Kobayashi, Shintaro Iwama, Yoshinori Yasuda, Journal of the Endocrine Society	2018	210
Intratumoral expression levels of <i>PD-L1</i>, <i>GZMA</i>, and <i>HLA-A</i> along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma Hiroyuki Inoue, Jae‐Hyun Park, Kazuma Kiyotani, OncoImmunology	2016	128
Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study Tomoko Kobayashi, Shintaro Iwama, Yoshinori Yasuda, Journal for ImmunoTherapy of Cancer	2020	120
Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma Yasuhiro Fujisawa, Shusuke Yoshikawa, Akane Minagawa, Cancer Medicine	2019	106
Effect of periodic operation over Pt catalysts in simulated oxidizing exhaust gas Hirofumi Shinjoh, Naoki Takahashi, Kenji Yokota, Applied Catalysis B: Environmental Chemical EngineeringCatalytic MaterialEngineeringPt CatalystsCombustion Science	1998	98
Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041) Naoya Yamazaki, Tatsuya Takenouchi, Manabu Fujimoto, Cancer Chemotherapy and Pharmacology Phase 1BAnti-pd-1 Monoclonal AntibodyMedicineMelanomaImmunology	2017	86
Determination of propagation and termination rate constants for some methacrylates in their radical polymerizations Kenji Yokota, Masaru Kani, Yoshio Ishii Journal of Polymer Science Part A-1 Polymer Chemistry EngineeringOrganic ChemistryChemistryRadical PolymerizationsPolymers	1968	85

Page 1